February 7, 2026
As the global toxicology community begins their spring trade show season and gathers for the annual meeting of the Society of Toxicology (SOT), representatives from Envol Biomedical will once again be attending to connect with researchers, sponsors, and partners shaping the future of preclinical drug development. The 2026 meeting, taking place in San Diego, remains one of the most influential events on the toxicology calendar, bringing together thousands of scientists from academia, industry, and regulatory agencies to exchange insights and discuss the evolving landscape of safety science.
For organizations developing new therapeutics, SOT provides a valuable opportunity to step back from the day-to-day pace of research and examine broader scientific and regulatory trends that are shaping the next generation of drug development programs. From emerging modalities to advances in analytical technologies and study design, the discussions taking place at SOT often reflect the questions sponsors are actively working through in their own pipelines. Envol’s team looks forward to participating in those conversations while meeting with colleagues and clients across the industry.
A Forum for Advancing Translational Toxicology
The SOT Annual Meeting has long served as a hub for collaboration between industry scientists, CRO partners, and academic researchers working to improve the predictive power of preclinical research. As therapeutic programs grow more complex—spanning biologics, gene therapies, cell-based medicines, and metabolic disease treatments—the expectations placed on toxicology studies continue to evolve alongside them.
At Envol, these shifts have reinforced the importance of thoughtful study design and translationally relevant models that generate meaningful insights early in development. Nonhuman primate (NHP) models continue to play a critical role in this process for many therapeutic areas, particularly when sponsors are evaluating biologics, complex biologic mechanisms, or therapies targeting physiological systems that cannot be replicated in smaller species. Conversations at SOT frequently explore how these models can be used more effectively—integrating pharmacology, toxicology, and biomarker strategies to support better decision-making as programs move toward clinical evaluation.
Supporting Sponsors Through Complex Development Programs
The Envol team attending SOT 2026 will be engaging with sponsors working across a wide range of therapeutic areas, including CNS disorders, metabolic disease, respiratory programs, and next-generation biologics. These discussions often center around the practical challenges that development teams encounter when transitioning from early discovery to IND-enabling studies and beyond.
Sponsors today are seeking partners who can provide more than just study execution. They increasingly need CRO teams capable of contributing to study design, surgical model development, complex dosing paradigms, and advanced physiological monitoring—all within the framework of GLP-compliant research environments. Envol’s integrated approach to pharmacology and toxicology studies, combined with its specialized NHP capabilities, continues to position the organization as a valuable collaborator for programs requiring highly controlled translational models.
The SOT meeting offers an ideal environment to discuss these topics directly with the scientists and development leaders who are navigating them. By engaging with researchers across academia, biotechnology, and large pharmaceutical companies, the Envol team gains valuable perspective on the evolving needs of the field while sharing insights drawn from their own work supporting complex preclinical programs.
Continuing the Conversation at SOT 2026
While the formal scientific sessions provide an important platform for presenting new research, many of the most productive conversations at SOT take place between presentations—in the hallways, poster sessions, and informal gatherings where scientists exchange ideas and experiences from their own development programs.
Members of the Envol team will be attending sessions throughout the meeting and connecting with colleagues across the toxicology community. For sponsors planning upcoming pharmacology or toxicology studies, SOT offers a convenient opportunity to discuss potential research strategies, explore new technologies, and learn how integrated preclinical programs can help reduce risk as therapies progress toward clinical trials. As the industry continues to push the boundaries of what is scientifically possible, events like SOT remain essential for fostering collaboration and sharing the knowledge that drives innovation forward. Envol Biomedical looks forward to being part of those conversations in San Diego and to continuing its work alongside the scientists and sponsors shaping the next generation of life-changing therapies.